JP2023519304A5 - - Google Patents

Info

Publication number
JP2023519304A5
JP2023519304A5 JP2022558042A JP2022558042A JP2023519304A5 JP 2023519304 A5 JP2023519304 A5 JP 2023519304A5 JP 2022558042 A JP2022558042 A JP 2022558042A JP 2022558042 A JP2022558042 A JP 2022558042A JP 2023519304 A5 JP2023519304 A5 JP 2023519304A5
Authority
JP
Japan
Prior art keywords
seq
antigen
cell
antibody
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022558042A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519304A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/024431 external-priority patent/WO2021195536A1/en
Publication of JP2023519304A publication Critical patent/JP2023519304A/ja
Publication of JP2023519304A5 publication Critical patent/JP2023519304A5/ja
Pending legal-status Critical Current

Links

JP2022558042A 2020-03-27 2021-03-26 多発性骨髄腫における免疫療法の標的およびその同定方法 Pending JP2023519304A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063000694P 2020-03-27 2020-03-27
US63/000,694 2020-03-27
PCT/US2021/024431 WO2021195536A1 (en) 2020-03-27 2021-03-26 Immunotherapeutic targets in multiple myeloma and methods for their identification

Publications (2)

Publication Number Publication Date
JP2023519304A JP2023519304A (ja) 2023-05-10
JP2023519304A5 true JP2023519304A5 (https=) 2024-02-27

Family

ID=77890610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022558042A Pending JP2023519304A (ja) 2020-03-27 2021-03-26 多発性骨髄腫における免疫療法の標的およびその同定方法

Country Status (8)

Country Link
US (1) US20230137672A1 (https=)
EP (1) EP4126243A4 (https=)
JP (1) JP2023519304A (https=)
KR (1) KR20220160053A (https=)
CN (1) CN116097096A (https=)
CA (1) CA3175860A1 (https=)
IL (1) IL296714A (https=)
WO (1) WO2021195536A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
WO2022031890A1 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Ifngr2 binding molecules and methods of use
US20230365696A1 (en) * 2020-08-05 2023-11-16 Synthekine, Inc. Ifngr1 binding molecules and methods of use
CN114031690B (zh) * 2021-12-03 2022-07-15 广州百暨基因科技有限公司 靶向ccr1和nkg2d配体的嵌合抗原受体及其应用
GB202117928D0 (en) 2021-12-11 2022-01-26 Cancer Research Tech Ltd Immunotherapy for cancer
CN116712550A (zh) * 2023-07-11 2023-09-08 中国医学科学院血液病医院(中国医学科学院血液学研究所) 治疗高增殖活性和多药耐药的多发性骨髓瘤的组合物及其应用
CN118501473A (zh) * 2024-05-22 2024-08-16 中国人民解放军海军军医大学第二附属医院 一种IgD型多发性骨髓瘤筛查试剂盒及其筛查系统
CN118878662A (zh) * 2024-09-03 2024-11-01 北京大学第六医院 多肽及其应用、试剂盒及其应用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6046012A (en) * 1993-07-19 2000-04-04 Hoffmann-La Roche Inc. Antibody to IL-12 receptor
US20030092002A1 (en) * 1997-09-17 2003-05-15 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU2048901A (en) * 1999-11-29 2001-06-04 Trustees Of Columbia University In The City Of New York, The Isolation of five novel genes coding for new Fc receptors-type melanoma involved in the pathogenesis of lymphoma/melanoma
US8679771B2 (en) * 2007-01-25 2014-03-25 The Regents Of The University Of California Specific N-terminal labeling of peptides and proteins in complex mixtures
WO2012022634A1 (en) * 2010-08-16 2012-02-23 Institut National De La Sante Et De La Recherche Medicale (Inserm) Classification, diagnosis and prognosis of multiple myeloma
GB2495113A (en) * 2011-09-29 2013-04-03 Bioinvent Int Ab Anti-ICAM-1 antibody for treating multiple-myeloma-related disorders
WO2014082083A1 (en) * 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
WO2015121454A1 (en) * 2014-02-14 2015-08-20 Cellectis Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells
GB201511191D0 (en) * 2015-06-25 2015-08-12 Immatics Biotechnologies Gmbh T-cell epitopes for the immunotherapy of myeloma
SI3331910T1 (sl) * 2015-08-03 2020-07-31 Engmab Sarl Monoklonska protitelesa proti humani antigen dozorevanja limfocitov B (BCMA)
CA2998611A1 (en) * 2015-09-14 2017-03-23 Leukemia Therapeutics, LLC Identification of novel diagnostics and therapeutics by modulating rhoh
US20170234874A1 (en) * 2015-10-07 2017-08-17 Clearbridge Biophotonics Pte Ltd. Integrated visual morphology and cell protein expression using resonance-light scattering
FR3051555B1 (fr) * 2016-05-20 2018-05-11 Horiba Abx Sas Detection de la maladie residuelle du myelome multiple
WO2018027197A1 (en) * 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Cancer antigen targets and uses thereof
BR112019006006A2 (pt) * 2016-09-28 2019-06-25 Gavish-Galilee Bio Applications Ltd. molécula de ácido nucleico, vetor, métodos para preparação de um receptor de antígeno quimérico inibidor, para preparar uma célula imune efetora segura, para selecionar um biomarcador personalizado e para tratar o câncer em um paciente com um tumor, célula imune efetora segura, e, combinação de duas ou mais moléculas de ácido nucleico.
LT3535392T (lt) * 2016-11-02 2024-04-25 Universität Basel Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje
WO2019094360A1 (en) * 2017-11-07 2019-05-16 The Board Of Regents Of The University Of Texas System Targeting lilrb4 with car-t or car-nk cells in the treatment of cancer
KR20250070609A (ko) * 2017-11-14 2025-05-20 아르셀엑스, 인크. 다기능성 면역 세포 요법
AU2018370217A1 (en) * 2017-11-17 2020-05-28 Memorial Sloan-Kettering Cancer Center Methods and compositions for alleviating Cytokine Release Syndrome
EA202091540A1 (ru) * 2017-12-22 2021-03-22 Джаунс Терапьютикс, Инк. Антитела к lilrb2
WO2020033585A1 (en) * 2018-08-07 2020-02-13 The Broad Institute, Inc. Methods for combinatorial screening and use of therapeutic targets thereof

Similar Documents

Publication Publication Date Title
JP2023519304A5 (https=)
JP7749055B2 (ja) 抗体送達のための組成物及び方法
CN112469829B (zh) 包含抗gpc3单链抗体的car
RU2761980C2 (ru) Композиции и способы лечения аутоиммунных заболеваний и рака
TW202206453A (zh) 表現嵌合抗原受體之病毒特異性免疫細胞
KR102316091B1 (ko) Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도
JP2018504094A (ja) Ｆｃ受容体様５を標的とするキメラ抗原受容体およびその使用
JP2018513687A5 (https=)
WO2017147538A1 (en) Transposon system and methods of use
KR20190111058A (ko) TGF-β 디코이 수용체
JP2022554395A (ja) がんを処置するためのスプライシング由来抗原の同定
CA3137788A1 (en) Allogeneic car-t cell, preparation therefor, and application thereof
WO2020018691A1 (en) Modified t cells and methods of their use
JP2023549342A (ja) 個別化されたがんワクチンのためのネオアンチゲンの選択
CN116583294A (zh) 抗炎细胞因子及其使用方法
KR20220108045A (ko) 공유 후보 항원 및 공유 항원-특이적 t 림프구 쌍을 확인 및 검증하기 위한 방법 및 시스템
CN115819592A (zh) 靶向ror1的抗原结合蛋白
JP2024539630A (ja) 抗ｓｔｅａｐ２キメラ抗原受容体及びその使用
JP4579836B2 (ja) 上皮細胞増殖因子受容体（ｅｇｆｒ）由来ペプチド
WO2022232797A2 (en) Virus-specific immune cells expressing chimeric antigen receptors
WO2022099126A1 (en) Anti-psma antibodies and methods of use
WO2022123613A1 (en) Car t cells for treating cd19+, cd20+ or cd22+ tumors or b-cell derived auto-immune diseases
JP2023179549A (ja) 腫瘍抗原をコードする麻疹ウイルス
IL296755A (en) Monoclonal antibodies targeting hsp70 and their therapeutic uses
CN115894691A (zh) 靶向ror1的抗原结合蛋白